In his 2011 Letter to Partners, Mr Sidibé outlines a set of six new frontiers to move the global AIDS response forward: The democratization of the response; making the law work for not against AIDS; reducing the upward trajectory of programme costs; making funding for AIDS a shared responsibility; making the AIDS movement a bridge to development; and fostering scientific innovation for HIV prevention and treatment.

This paper reviews how countries can successfully use the flexibilities of the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to increase access to HIV treatment.

(UNAIDS/UNDPKO, May 2011)

Many countries with a high burden of HIV infection also face burgeoning epidemics of noncommunicable diseases. Similar to HIV, noncommunicable diseases are most frequent in low- and middle-income countries, and the age-adjusted death rates from noncommunicable diseases are nearly twice as high in low- and middle-income countries as in high-income countries. People living with HIV often also have high rates of noncommunicable diseases. With HIV programmes rapidly expanding, people with HIV are living longer and ageing, and are developing non-HIV-related chronic conditions similar to the rest of the population.

We live in a time of unprecedented hope for the 33.3 million people living with HIV worldwide. Antiretroviral therapy (ART) offers the promise of a full and fulfilling life. Now people living with HIV can raise their families, work and pursue their dreams. But a thief is in our midst—one that is routinely robbing people, and the countries they live in, of their futures. Every minute, three people living with HIV have their lives snatched away by tuberculosis (TB). Africa, hit hard by HIV, is also hit hard by TB. TB is the main cause of death in people living with HIV.

The good participatory practice (GPP) guidelines provide trial funders, sponsors, and implementers with systematic guidance on how to effectively engage with stakeholders in the design and conduct of biomedical HIV prevention trials. In the GPP guidelines, “design and conduct of biomedical HIV prevention trials” refers to activities required for the development, planning, implementation, and conclusion of a trial, including dissemination of trial results.

The primary goals of Positive Health, Dignity and Prevention are to improve the dignity, quality, and length of life of people living with HIV; which, if achieved will, in turn, have a beneficial impact on their partners, families, and communities, including reducing the likelihood of new infections.

This publication describes how the Joint United Nations Programme on HIV/AIDS (UNAIDS) partners with country partners and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to strengthen the global response to AIDS and to accelerate progress towards universal access to HIV prevention, treatment, care and support, and the achievement of the Millennium Development Goals (MDGs).

This report shows that these global commitments will be achieved only if the unique needs of young women and men are acknowledged, and their human rights fulfilled, respected, and protected. In order to reduce new HIV infections among young people, achieve the broader equity goals set out in the MDGs, and begin to reverse the overall HIV epidemic, HIV prevention and treatment efforts must be tailored to the specific needs of young people.